Home › Companies › Spero Therapeutics, Inc.

Spero Therapeutics, Inc. (SPRO) proxy voting records

How asset managers voted at Spero Therapeutics, Inc.’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

TickerSPRO
CUSIP issuer number84833T
SEC CIK1701108

Recent shareholder votes

May 29, 2024 annual meeting (2023-2024 proxy season): 6 items in Spero Therapeutics, Inc.'s official results (Form 8-K, filed June 3, 2024); lowest support 92% of votes cast (Amendment to the 2017 Plan). Full results and how funds voted.
October 5, 2023 annual meeting (2023-2024 proxy season): 8 items in Spero Therapeutics, Inc.'s official results (Form 8-K, filed October 10, 2023); lowest support 87% of votes cast (Elect Director: Milind Deshpande, Ph.D.). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Season	Filed as	Ballot items	Asset managers
2025-2026	Spero Therapeutics, Inc.	7	50
2023-2024	SPERO THERAPEUTICS INC.	15	73

Earlier seasons list this company under the name SPERO THERAPEUTICS INC., as its holders filed it.

Explore Spero Therapeutics, Inc. in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. Ticker as listed by the SEC on November 6, 2026. This page is rebuilt weekly; built November 9, 2026.